natgillin/translations-raw huggingface dataset:
An active infection at the operative site
akutno okužbo v operativnem območju;
An active ingredient of Porcilis AR-T DF, Pasteurella multocida toxin, is produced by a method known as ‘recombinant technology’.
Zdravilna učinkovina zdravila Porcilis AR-T DF, toksin Pasteurella multocida, se proizvaja z metodo, imenovano rekombinantna tehnologija.
an Acute Coronary Syndrome (unstable angina, NSTEMI and STEMI) (see section 4.4)
z akutnim koronarnim sindromom (nestabilna angina pektoris, NSTEMI in STEMI) (glejte poglavje 4.4)
An acute ocular infection may be masked by the topical use of anti-inflammatory medicinal products.
Topična uporaba protivnetnih zdravil lahko prikrije akutno okužbo očesa.
An acute ocular infection may be masked by the topical use of anti-inflammatory medicines.
Pri topikalni uporabi lahko zdravila proti vnetju prikrijejo znake akutne očesne okužbe.
An ad hoc efficacy analysis was performed after all patients who had received lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg q12h) in Trial 1 or Trial 2 had completed the Week 24 Visit in Trial 3 (up to 48 weeks of treatment).
Potem ko so vsi bolniki, ki so prejemali lumakaftor/ivakaftor (lumakaftor 400 mg/ivakaftor 250 mg na 12 ur) v preskušanju 1 ali preskušanju 2, opravili pregled v 24. tednu v preskušanju 3 (do 48 tednov zdravljenja), so izvedli ad hoc analizo učinkovitosti.
An add-on placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with glibenclamide in patients with inadequate glycaemic control at enrollment (HbA1c 7.5-10%) on a sub-maximal dose of glibenclamide alone.
Narejena je bila 24-tedenska s placebom kontrolirana študija za oceno učinkovitosti in varnosti saksagliptina v kombinaciji z glibenklamidom pri bolnikih, ki ob vključitvi z uporabo submaksimalnega odmerka samega glibenklamida niso imeli ustrezno urejene glikemije (HbA1c od 7,5 % do 10 %).
An add-on to metformin placebo-controlled study of 12-week duration was conducted to evaluate the efficacy and safety of saxagliptin 2.5 mg twice daily in combination with metformin in patients with inadequate glycaemic control (HbA1c 7-10%) on metformin alone.
7-10 %), je bila opravljena 12—tedenska, s placebom kontrolirana, študija za oceno učinkovitosti in varnosti 2,5 mg saksagliptina dvakrat na dan v kombinaciji z metforminom.
An add-on to metformin placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with metformin in patients with inadequate glycaemic control (HbA1c 7-10%) on metformin alone.
Narejena je bila 24-tedenska s placebom kontrolirana študija za oceno učinkovitosti in varnosti saksagliptina v kombinaciji z metforminom pri bolnikih, ki med monoterapijo z metforminom glikemije niso imeli ustrezno urejene (HbA1c od 7 % do 10 %).
An add-on to metformin placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with metformin in patients with inadequate glycaemic control (HbA1c 7-10%) on metformin alone.
Opravljena je bila 24—tedenska, s placebom kontrolirana, študija dodatka k metforminu za oceno učinkovitosti in varnosti saksagliptina v kombinaciji z metforminom pri bolnikih, ki s samim metforminom glikemije niso imeli dovolj urejene (HbA1c od 7-10 % ).
An additional 4 patients made motor development gains during the study and were sitting independently by the last study assessment (with individual patient treatment durations ranging from 78 to 130 weeks; mean follow-up period of weeks), although they did not have functional use of the legs.
Dodatni 4 bolniki so med študijo motorično napredovali in so samostojno sedeli do zadnje ocene študije (s trajanjem zdravljenja pri posameznih bolnikih v razponu od 78 do 130 tednov; povprečno obdobje sledenja 110 tednov), čeprav nog niso funkcionalno uporabljali.
An additional 4% (n=27) of patients from the two studies had incomplete MTTs and were not randomised.
Dodatnih 4 % (n=27) preiskovancev v obeh študijah ni imelo popolno opravljenega testa MTT, zato niso bili randomizirani.
An additional air buffer of at least 3 ml is included in the 50 ml syringe.
50 ml brizga vključuje vsaj dodatne 3 ml zračnega pufra.
An additional analysis of efficacy data by KRAS status did not identify a subset of patients who benefited from Vectibix in combination with oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
Dodatna analiza podatkov o učinkovitosti glede na stanje KRAS ni odkrila podskupine bolnikov, ki bi jim bil koristilo zdravilo Vectibix v kombinaciji s kemoterapijo na podlagi oksaliplatina ali irinotekana ter bevacizumab.
An additional dose of 50 U/kg was administered for 13/133 (10%) attacks.
Dodatni odmerek 50 e./kg je bil dan pri 13/133 (10 %) napadih.
An additional five studies looked at the effects of a booster vaccination with Infanrix hexa.
V dodatnih petih študijah so proučevali učinke obnovitvenega cepljenja s cepivom Infanrix hexa.
An additional four HES patients were found to be FIP1L1- PDGFRα-positive in other 3published reports.
FIP1L1- PDGFRα pozitivni so bili še štirje bolniki s HES, ki so jih opisovali v drugih 3 objavljenih poročilih.
An additional infusion, given at least one year after the first one, can be considered if the patient’s disease comes back.
O dodatnem infundiranju, ki se da najmanj eno leto po prvem, se lahko razmisli, če se bolezen pri bolniku ponovi.
An additional observation of an increased incidence of bone fractures was seen in women with rosiglitazone (see sections 4.4 and 4.8).
Dodatno so pri ženskah med uporabo rosiglitazona opazili večjo incidenco zlomov kosti (glejte poglavji 4.4 in 4.8)..
An additional one to two Suboxone 2 mg/0.5 mg may be administered on day one depending on the individual patient’s requirement.
Dodatni ena ali dve tableti zdravila Suboxone 2 mg/0,5 mg se lahko da prvega dne, kar je odvisno od zahtev posameznega bolnika.
An additional one to two tablets of the Suboxone 2 mg/0.5 mg may be administered on day 1 depending on your needs.
Na 1. dan lahko glede na svoje potrebe vzamete dodatno eno ali dve tableti zdravila Suboxone 2 mg/0,5 mg.
An additional overall survival analysis was undertaken based upon the 20 May 2013 data cut, see Table 9.
Dodatna analiza celokupnega preživetja je bila opravljena na podlagi podatkov do 20. maja 2013, glejte preglednico 9.
An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered (see vial content table below).
Vsaka viala vsebuje dodatno prepolnjenje, ki zagotavlja, da je mogoče iz nje dobiti 250 µg romiplostima (glejte tabelo Vsebina viale spodaj).
An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered (see vial content table below). or
Vsaka viala vsebuje dodatno prepolnjenje, ki zagotavlja, da je mogoče iz nje dobiti 250 µg romiplostima (glejte tabelo Vsebina viale spodaj). ali
An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered.
Vsaka viala vsebuje presežek, ki zagotavlja, da je mogoče iz nje dobiti 250 µg romiplostima.
An additional overfill is included in each vial to ensure that 500 µg of romiplostim can be delivered (see vial content table below).
Vsaka viala vsebuje dodatno prepolnjenje, ki zagotavlja, da je mogoče iz nje dobiti 500 µg romiplostima (glejte tabelo Vsebina viale spodaj).
An additional overfill is included in each vial to ensure that 500 µg of romiplostim can be delivered.
Vsaka viala vsebuje presežek, ki zagotavlja, da je mogoče iz nje dobiti 500 µg romiplostima.
An additional retrospective analysis showed a nominally significant reduction in the incidence rates of stent thrombosis compared with placebo (see Table 3).
Dodatna retrospektivna analiza je pokazala nominalno pomembno zmanjšanje incidence tromboze stenta v primerjavi s placebom (glejte preglednico 3).
An additional study compared Cimzia given alone with placebo in 218 patients whose response to other medicines such as methotrexate had been inadequate.
V dodatni študiji so zdravilo Cimzia kot samostojno zdravilo primerjali s placebom pri 218 bolnikih, ki se niso zadostno odzvali na druga zdravila, kot je npr. metotreksat.
An additional study in 118 patients was carried out to test that loading doses of 200 mg Vimpat by infusion, followed by maintenance doses taken by mouth, can be applied safely and that adequate levels in the body are achieved.
Nadaljnja dodatna študija je bila izvedena pri 118 bolnikih z namenom proučevanja varnosti infundiranja 200-miligramskega udarnega odmerka zdravila Vimpat, ki mu sledijo vzdrževalni odmerki, zaužiti peroralno, in ugotavljanja, ali to pripelje do ustreznih ravni zdravilne učinkovine v telesu.
An additional study in 208 children compared the vaccine’s effectiveness when a six-month or a 12-month interval was used between the two injections.
V dodatni študiji so pri 208 otrocih primerjali učinkovitost cepiva pri šestmesečnem ali dvanajstmesečnem intervalu med dvema cepljenjema.
An additional study in 945 previously untreated advanced melanoma patients investigated Opdivo in combination with ipilimumab, Opdivo used alone or ipilimumab used alone.
V dodatni študiji pri 945 predhodno nezdravljenih bolnikih z melanomom so preiskovali uporabo zdravila Opdivo v kombinaciji z ipilimumabom, samostojno uporabo zdravila Opdivo ali samostojno uporabo ipilimumaba.
An additional study in adults with schizophrenia looked at the long-term effects of Invega in preventing new symptoms for up to 35 weeks in 207 patients who had initially been treated over a 14-week period, and another study involving 228 adolescents looked at the longer-term effects of treatment with Invega over 8 and 26 weeks compared with aripiprazole (another antipsychotic medicine).
V dodatni študiji pri odraslih bolnikih s shizofrenijo so pri 207 bolnikih, ki so bili na začetku zdravljeni 14 tednov, proučevali dolgoročne učinke zdravila Invega pri preprečevanju pojava novih simptomov v obdobju do 35 tednov, v drugo študijo pa je bilo vključenih 228 mladostnikov, pri katerih so proučevali dolgoročne učinke zdravljenja z zdravilom Invega v obdobju od 8 do 26 tednov v primerjavi z aripiprazolom (drugim antipsihotikom).
An additional study looked at the effectiveness of Exjade in 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia.
V dodatni študiji so učinkovitost zdravila Exjade proučevali pri 184 bolnikih, ki niso mogli jemati deferoksamina, med katerimi so bili bolniki z beta talasemijo major in drugimi vrstami slabokrvnosti.
An additional study measured the ‘acceptability’ of PecFent, by the patients rating how satisfied they were with PecFent, and how easy and convenient they found it to use.
V dodatni študiji so merili „sprejemljivost“ zdravila PecFent, pri kateri so bolniki ocenjevali svoje zadovoljstvo z zdravilom PecFent ter enostavnost in priročnost njegove uporabe.
An additional study showed Viekirax to be effective against genotype 4: when given with ribavirin, Viekirax cleared this genotype from the blood of all the 91 patients infected with it after 12 weeks.
V dodatni študiji se je zdravilo Viekirax izkazalo za učinkovito proti genotipu 4: v kombinaciji z ribavirinom je to zdravilo po 12 tednih ta genotip odstranilo iz krvi vseh 91 bolnikov, okuženih z njim.
An additional study was also carried involving 250 patients with ankylosing spondylitis out to show that Remsima produces levels of the active substance in the body that are comparable to the reference medicine, Remicade.
Opravili so tudi dodatno študijo z 250 bolniki z ankilozirajočim spondilitisom, s katero so želeli dokazati, da so ravni zdravilne učinkovine v telesu po uporabi zdravila Remsima primerljive z ravnmi po uporabi referenčnega zdravila Remicade.
An additional study was also used to support the main study and to demonstrate the vaccine’s safety.
V podporo glavni študiji in za dokazovanje varnosti cepiva je bila izvedena dodatna študija.
An additional study was carried out in 267 hepatitis C patients whose liver was not working properly (Child-Pugh class B cirrhosis).
Pri 267 bolnikih s hepatitisom C, pri katerih jetra niso delovala pravilno (ciroza stopnje B po Child- Pughu), so opravili dodatno študijo.
An additional study will look at the safety and use of Blincyto in clinical practise.
V dodatni študiji se bosta proučevali varnost in uporaba zdravila Blincyto v klinični praksi.
An additional tablespoon of food is added to the small container for thorough delivery of the powder from the container and contents are mixed.The entire residual mixture is fed to the child.
V manjšo posodico dodajte še eno jedilno žlico hrane in jo dobro pomešajte po posodici, da zajamete še morebitni preostali prašek v posodici.
an adhesive bandage a container for the waste material
obliž, vsebnik za odpadni material.
an adhesive plaster a proper disposal container for used needles, syringe and vials (sharps container)
adhezivni obliž ustrezen zabojnik za uporabljene igle, brizge in viale (zbiralnik za ostre predmete)
an adhesive plaster disposal box for used syringes and needles
lepljivi obliž posodo za uporabljene injekcijske brizge in igle
an adhesive plaster disposal box for used syringes and needles.
amolepilni obliž škatla za odstranjevanje brizg in igel.
An adverse reaction is only presented for the fixed dose combination if it has not been seen in one of the component parts of AVAGLIM or if it occurred at a higher frequency than that listed for a component part.
Neželeni učinki kombinacije v fiksnem odmerku so navedeni le, če pri posamezni zdravilni učinkovini zdravila AVAGLIM niso bili ugotovljeni, oziroma je bila njihova pogostnost večja od pogostnosti pri posamezni zdravilni učinkovini.
An agency of the European Union
Agencija Evropske unije
An agency of the European Union
An agency of the European Union  injekcijo.
An agency of the European Union within two years for people from six years of age, and within six months for children aged between two and six years.
An agency of the European Union odmerek, ki se osebam, starejšim od šest let, daje po dveh letih, otrokom, starim od dveh do šest let, pa po šestih mesecih.
An air bubble is large if it fills the tip of the reservoir holder when holding the pre-filled pen with the needle pointing upwards (see picture).
Zračni mehurček se šteje za velikega, če napolni zgornji del prostora za tekočino, ko napolnjen injekcijski peresnik držite tako, da je igla obrnjena navzgor (glejte sliko).
An alcohol swab.
alkoholni zloženec,
an alcohol wipe,
alkoholni čistilni robček,
an alcohol wipe,
alkoholno krpico,
an alcohol wipe, a piece of gauze bandage or a sterile gauze swab.
alkoholni čistilni robček, košček povoja iz gaze ali sterilno vatno blazinico.
an alcohol wipe, a piece of gauze bandage or a sterile gauze swab.
alkoholno krpico, kos gaze ali sterilnega zloženca.
An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Alergijske reakcije - to se zgodi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Alergijske reakcije-to se zgodi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people).
Alergijska reakcija – to se zgodi občasno (pojavi se lahko pri največ 1 od 100 bolnikov).
An allergic reaction -this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Alergijske reakcije - to se zgodi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
An allergic reaction can include a rash, itching or shortness of breath.
Alergijska reakcija lahko vključuje izpuščaje, srbenje ali oteženo dihanje.
An allergic reaction in the eye
alergijska reakcija v očesu,
An allergic reaction to eggs or anything that contained egg.
Alergijska reakcija na jajca ali na karkoli, kar vsebuje jajca.
an allergic reaction which can cause rash, wheals/weals, swelling under the skin near the eyes or throat, throat tightness, difficulty breathing
alergijska reakcija, ki lahko povzroči izpuščaje, izbočene lise, podkožno oteklino blizu oči ali grla, stiskanje v grlu in težave z dihanjem
An allergic reaction – (this occurs uncommonly may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
Alergijske reakcije - to se zgodi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
An allergic reaction, which may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat, difficulty breathing or swallowing, itching
alergijska reakcija, ki lahko vključuje koprivnico, srbenje, izpuščaj, otekanje obraza, ustnic, jezika ali grla, težave pri dihanju ali požiranju, srbenje;
an allergy to latex (the needle cover on the pre-filled syinge contains a derivative of latex).
alergijo na lateks (pokrovček igle na napolnjeni injekcijski brizgi vsebuje snov, pridobljeno iz lateksa).
An allergy to midazolam, benzodiazepines (such as diazepam) or any of the other ingredients of this medicine (listed in section 6)
alergijo na midazolam, benzodiazepine (kot je diazepam) ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
an alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign prostatic hyperplasia).
antagonist adrenergičnih receptorjev alfa (ki se uporablja za zdravljenje visokega krvnega tlaka ali simptomov sečil, povezanih z benigno hiperplazijo prostate).
An alternate (non- hormonal) reliable method of contraception is recommended.
Priporočamo uporabo druge (nehormonske) zanesljive metode kontracepcije.
An alternate pathway of biotransformation involves -oxidation via 3,4-dihydroxybutyrate to Acetyl CoA, which also enters the citric acid cycle to result in the formation of carbon dioxide and water.
Alternativna pot biotransformacije vključuje -oksidacijo preko 3,4- dihidroksibutirata do acetil-CoA, ki prav tako vstopa v ciklus trikarboksilnih kislin, kjer nastajata ogljikov dioksid in voda.
An alternate reliable
Priporočljiva je uporaba druge zanesljive metode kontracepcije.
An alternative treatment should be considered in such situations.
V takšnih primerih je treba razmisliti o uporabi drugega zdravila.
An Amyvid PET scan, along with other brain function tests, can help your doctor determine whether or not you may have β-amyloid plaques in your brain.
PET-preiskava z zdravilom Amyvid, skupaj z drugimi testi delovanja možganov, lahko vašemu zdravniku pomaga ugotoviti, ali imate v možganih β- amiloidne lehe.
An analysis of 22 cases of erythema multiforme reported as serious adverse events for alogliptin containing medicinal products indicated that a relationship between the event and alogliptin seems likely since there were 7 serious cases without confounding factors, and 16 of the 22 serious cases reported a positive dechallenge.
Analiza 22 primerov multiformnega eritema, o katerem so poročali kot o resnem neželenem učinku pri uporabi zdravil, ki vsebujejo alogliptin, je pokazala, da je povezava med neželenim učinkom in uporabo alogliptina verjetna, saj pri 7 resnih primerih niso ugotovili drugih možnih dejavnikov, pri 16 od 22 resnih primerov pa je neželeni učinek po prekinitvi uporabe zdravila izzvenel.
An analysis of non-CABG-related bleeding is presented in Table 2.
Analiza krvavitev, ki ni povezana s kirurškim posegom aortokoronarnega obvoda (CABG, Coronary Artery Bypass Graft), je predstavljena v preglednici 2.
An analysis of safety data in patients 60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients <60 years of age.
Analiza varnostnih podatkov pri bolnikih, starih 60 let ali več, ki so bili zdravljeni le s kapecitabinom, in tistih, ki so prejemali kapecitabin v kombinaciji z docetakselom, je pokazala, da je pogostnost z zdravljenjem povezanih neželenih učinkov stopnje 3 in 4 ter z zdravljenjem povezanih resnih neželenih učinkov večja kot pri bolnikih, mlajših od 60 let.
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n = 399, 9.3 versus
Analiza vpliva histologije NSCLC glede učinka zdravljenja na skupno preživetje je bila prednostna za pemetreksed proti docetakselu pri tistih, ki nimajo pretežno luskaste histologije (n = 399, 9,3 proti 8,0 mesecev, prilagojen RT = 0,78; 95 % IZ
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n = 399, 9.3 versus
Analiza vpliva histologije NSCLC glede učinka zdravljenja na skupno preživetje je bila prednostna za pemetreksed proti docetakselu pri tistih, ki nimajo pretežno ploščatocelične histologije (n = 399, 9,3 proti
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (N = 399, 9.3 versus 8.0 months, adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (N =172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018).
Analiza vpliva histologije NSCLC glede učinka zdravljenja na skupno preživetje je bila prednostna za pemetreksed proti docetakselu pri tistih, ki nimajo pretežno luskaste histologije (n = 399, 9,3 proti 8,0 mesecev, prilagojen RT = 0,78; 95 % IZ = 0,61-1,00, p = 0,047) in je bila prednostna za docetaksel za luskasto celično histologijo karcinoma (n = 172, 6,2 proti 7,4 mesecev, prilagojen RT = 1,56; 95 % IZ = 1,08- 2,26, p = 0,018).
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n= 399, 9.3 versus
V skladu z ostalimi študijami pemetrekseda so v študiji JMEN tudi opažali razliko v učinkovitosti glede na histologijo NSCLC.
An analysis of tropism following failure of maraviroc therapy with CXCR4-using virus in patients with CCR5 virus at baseline, demonstrated that the virus population reverted back to CCR5 tropism in 33 of 36 patients with more than 35 days of follow-up.
Analiza tropizma po neuspehu terapije z maravirokom ob virusu uporabniku CXCR4 pri bolnikih s CCR5 virusom v izhodišču, je pokazala, da se je med več kot 35 dnevnim spremljanjem populacija virusov povrnila v CCR5-tropizem pri 33 od 36 bolnikov.
An anaphylactic reaction was reported in a post-marketing clinical study in a patient who had previous exposure to Xiapex for the treatment of Dupuytren’s contracture, demonstrating that severe reactions including anaphylaxis can occur following Xiapex injections.
Iz klinične študije v obdobju trženja zdravila so poročali o anafilaktični reakciji pri bolniku, ki je bil predhodno izpostavljen zdravilu Xiapex zaradi zdravljenja Dupuytrenove kontrakture, kar kaže na to, da se lahko po injiciranju zdravila Xiapex pojavijo hude reakcije, vključno z anafilaksijo.